The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Neuroinflammatory perspectives on the two faces of Alzheimer?s disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“Activated microglial cells, particularly those in the vicinity of neuritic plaques have shown to be immunoreactive for interleukin-1 (Il-1), interleukin-6 (Il-6), and tumour necrosis factor-a (TNF-a) (Griffin et al., 1989; Dickson et al., 1993, Huell et al., 1995).”
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 2×
“Another inflammation-based therapeutic approach for treatment AD is immunization with Ab (Schenk et al., 1999) but this therapeutic option is hampered by severe side effects (Nicoll et al., 2003).”
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“In addition, these classical NSAIDS have also a direct lowering effect on Ab1–42 production independently of the cyclooxygenase inhibitory effect (Weggen et al., 2001).”
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“The idea that the neuroinflammatory response is an interesting target for treatment with anti-inflammatory drugs was stimulated by epidemiological studies showing that the use of classical NSAIDs can prevent or retard AD (McGeer et al., 1996; In ‘t Veld et al., 2001).”
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Inflammatory markers and cognition in well-functioning African-American and white elders
Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S., & Harris, T. (2003) · Neurology · doi:10.1212/01.wnl.0000073620.42047.d7 · Cited by 706 · cited 2×
“In prospective case-cohort studies it is found that high serum levels of the acute phase proteins ACT, C-reactive protein and Il-6 and low serum levels of insulin-growth factor-1 were each associated with an increased risk of AD (Engelhart, 2002; Schmidt et al., 2002; Dik et al., 2003; Yaffe et al., 2003).”
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446
The impact of systemic infection on the progression of neurodegenerative disease
Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428
Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease
Vehmas, A. K., Kawas, C. H., Stewart, W. F., & Troncoso, J. C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00090-8 · Cited by 230
Huell, M., Strauss, S., Volk, B., Berger, M., & Bauer, J. (1995) · Acta Neuropathologica · doi:10.1007/bf00571510 · Cited by 214 · cited 1×
“Activated microglial cells, particularly those in the vicinity of neuritic plaques have shown to be immunoreactive for interleukin-1 (Il-1), interleukin-6 (Il-6), and tumour necrosis factor-a (TNF-a) (Griffin et al., 1989; Dickson et al., 1993, Huell et al., 1995).”
The role of complement and activated microglia in the pathogenesis of Alzheimer's disease
Eikelenboom, P., & Veerhuis, R. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00108-x · Cited by 206
Self-citationIncreased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
Cited by
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
“colocalized with clusters of activated microglia (18).”
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice
Zhao, J., Bi, W., Xiao, S., Lan, X., Cheng, X., Zhang, J., Lu, D., Wei, W., Wang, Y., Li, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42286-8 · Cited by 896
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World Journal · doi:10.1100/2012/756357 · Cited by 839
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Metadata
- Authors
- Eikelenboom, P., & van Gool, W. A.
- Venue
- Journal of Neural Transmission
- Published
- 2004-03-01
- Volume
- 111
- Issue
- 3
- Pages
- 281-294
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W1998849703
- Cited by
- 182
- References
- 14
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.